Abdullah Shafique Ahmad1, Zahoor Ahmad Shah2, Sylvain Doré3. 1. Department of Anesthesiology, University of Florida, Gainesville, 32610, FL, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, 32610, FL, USA. 2. Department of Medicinal and Biological Chemistry, University of Toledo, Toledo 43614, OH, USA. 3. Department of Anesthesiology, University of Florida, Gainesville, 32610, FL, USA; Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, 32610, FL, USA; Departments of Neurology, Psychiatry, Psychology, Pharmaceutics, and Neuroscience, University of Florida, Gainesville, 32610 FL, USA.
Abstract
BACKGROUND: Arginase (Arg), one of the enzymes involved in the urea cycle, provides an essential route for the disposal of excess nitrogen resulting from amino acid and nucleotide metabolism. Two reported subtypes of Arg (ArgI and II) compete with nitric oxide synthase (NOS) to use L-arginine as a substrate, and subsequently regulate NOS activity. It has been reported that Arg has significant effects on circulation that suggest the potential role of this enzyme in regulating vascular function. However, the role of Arg following brain damage has not been elucidated. In this study, we hypothesize that the deletion of ArgII will lead to aggravated brain injury following cerebral ischemia and excitotoxicity. METHODS AND FINDINGS: To test our hypothesis, male C57BL/6 wildtype (WT) and ArgII-/- mice were subjected to permanent distal middle cerebral artery occlusion and survived for 7 d. Cerebral blood flow (CBF) data revealed a statistically non-significant decrease in CBF in ArgII-/- mice. However, ArgII-/- mice had significantly higher neurologic deficit scores and brain infarctions. The hypothesis was further tested in a more specific N-methyl-D-aspartate (NMDA)-induced acute excitotoxic model. WT and ArgII-/- mice were given a single intrastriatal injection of 15 nmol NMDA. Forty-eight hours later, the excitotoxic brain damage was significantly worse in ArgII-/- mice. The data from both models confirm the neuroprotective effect of ArgII. CONCLUSION: Targeting ArgII could be considered an integrative part of a multi-modal approach to fight acute brain damage excitotoxicity, ischemic brain injury, and other forms of brain trauma.
BACKGROUND: Arginase (Arg), one of the enzymes involved in the urea cycle, provides an essential route for the disposal of excess nitrogen resulting from amino acid and nucleotide metabolism. Two reported subtypes of Arg (ArgI and II) compete with nitric oxide synthase (NOS) to use L-arginine as a substrate, and subsequently regulate NOS activity. It has been reported that Arg has significant effects on circulation that suggest the potential role of this enzyme in regulating vascular function. However, the role of Arg following brain damage has not been elucidated. In this study, we hypothesize that the deletion of ArgII will lead to aggravated brain injury following cerebral ischemia and excitotoxicity. METHODS AND FINDINGS: To test our hypothesis, male C57BL/6 wildtype (WT) and ArgII-/- mice were subjected to permanent distal middle cerebral artery occlusion and survived for 7 d. Cerebral blood flow (CBF) data revealed a statistically non-significant decrease in CBF in ArgII-/- mice. However, ArgII-/- mice had significantly higher neurologic deficit scores and brain infarctions. The hypothesis was further tested in a more specific N-methyl-D-aspartate (NMDA)-induced acute excitotoxic model. WT and ArgII-/- mice were given a single intrastriatal injection of 15 nmol NMDA. Forty-eight hours later, the excitotoxic brain damage was significantly worse in ArgII-/- mice. The data from both models confirm the neuroprotective effect of ArgII. CONCLUSION: Targeting ArgII could be considered an integrative part of a multi-modal approach to fight acute brain damage excitotoxicity, ischemic brain injury, and other forms of brain trauma.
Authors: A Majid; Y Y He; J M Gidday; S S Kaplan; E R Gonzales; T S Park; J D Fenstermacher; L Wei; D W Choi; C Y Hsu Journal: Stroke Date: 2000-11 Impact factor: 7.914
Authors: Jochen Steppan; Sungwoo Ryoo; Karl H Schuleri; Chris Gregg; Rani K Hasan; A Ron White; Lukasz J Bugaj; Mehnaz Khan; Lakshmi Santhanam; Daniel Nyhan; Artin A Shoukas; Joshua M Hare; Dan E Berkowitz Journal: Proc Natl Acad Sci U S A Date: 2006-03-13 Impact factor: 11.205
Authors: Louis G Chicoine; Michael L Paffett; Tamara L Young; Leif D Nelin Journal: Am J Physiol Lung Cell Mol Physiol Date: 2004-02-20 Impact factor: 5.464
Authors: Terry Jo V Bichell; Michal Wegrzynowicz; K Grace Tipps; Emma M Bradley; Michael A Uhouse; Miles Bryan; Kyle Horning; Nicole Fisher; Karrie Dudek; Timothy Halbesma; Preethi Umashanker; Andrew D Stubbs; Hunter K Holt; Gunnar F Kwakye; Andrew M Tidball; Roger J Colbran; Michael Aschner; M Diana Neely; Alba Di Pardo; Vittorio Maglione; Alexander Osmand; Aaron B Bowman Journal: Biochim Biophys Acta Mol Basis Dis Date: 2017-02-16 Impact factor: 5.187
Authors: R William Caldwell; Paulo C Rodriguez; Haroldo A Toque; S Priya Narayanan; Ruth B Caldwell Journal: Physiol Rev Date: 2018-04-01 Impact factor: 37.312
Authors: Abdelrahman Y Fouda; Wael Eldahshan; S Priya Narayanan; R William Caldwell; Ruth B Caldwell Journal: Front Pharmacol Date: 2020-03-17 Impact factor: 5.810
Authors: Gonçalo S Clemente; Aren van Waarde; Inês F Antunes; Alexander Dömling; Philip H Elsinga Journal: Int J Mol Sci Date: 2020-07-25 Impact factor: 5.923